Westshore Wealth’s Insight Molecular Diagnostics IMDX Stock Holding History

Westshore Wealth’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,000	Closed	-$7.09K	–	118
2023 Q1	$7.09K	Hold	1,000	–	–	﹤0.01%	111
2022 Q4	$6.42K	Hold	1,000	–	–	﹤0.01%	104
2022 Q3	$15K	Hold	1,000	–	–	0.01%	92
2022 Q2	$18K	Hold	1,000	–	–	0.01%	94
2022 Q1	$30K	Hold	1,000	–	–	0.02%	95
2021 Q4	$43K	Hold	1,000	–	–	0.03%	90
2021 Q3	$71K	Hold	1,000	–	–	0.06%	78
2021 Q2	$115K	Hold	1,000	–	–	0.06%	139
2021 Q1	$104K	Buy	+1,000	New	+$95K	0.06%	142

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Westshore Wealth's IMDX Position: Q2 2023 in Review

Westshore Wealth sold out of Insight Molecular Diagnostics (IMDX) in Q2 2023, closing a stake of 1,000 shares — an estimated $7.09K sold.

Westshore Wealth first reported a position in IMDX in Q1 2021 and held it in 9 quarters. The position peaked at $115K in Q2 2021. 47 funds tracked by Wall St. Rank hold IMDX as of Q2 2023.

Westshore Wealth reported no remaining Insight Molecular Diagnostics position as of Q2 2023 after selling out during the quarter.
Westshore Wealth sold 1,000 Insight Molecular Diagnostics shares in Q2 2023, an estimated $7.09K.
Westshore Wealth first reported a position in Insight Molecular Diagnostics in Q1 2021 and held it in 9 quarters.
Westshore Wealth's Insight Molecular Diagnostics position peaked at $115K in Q2 2021.
47 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2023.

Based on Westshore Wealth's 13F filing for Q2 2023, filed 5 Sep 2023.